Some Crohn’s Disease Patients Reach Remission with Risankizumab

Some Crohn’s Disease Patients Reach Remission with Risankizumab
Phase 2 clinical trial results showed that patients with moderate to severe active Crohn's disease can achieve disease remission when treated with risankizumab, a Boehringer Ingelheim investigational biologic product. The study, “IL-23 Inhibitor Risankizumab Induces Remission in Phase II Study in Patients with Moderate-to-Severe Crohn's Disease,” was presented during the Digestive Disease Week (DDW) Conference in San Diego, Calif. In the study, patients with active Crohn's disease were randomly treated for 12 weeks either with placebo or risankizumab. After 12 weeks, 24% of patients treated with
Subscribe or to access all post and page content.

One comment

  1. John reynolds says:

    Raising sufferers hope is cruel. Please find the cause then maybe just maybe a cure or true effective treatment can be guaranteed

Leave a Comment

Your email address will not be published. Required fields are marked *